Marker antibodies in scleroderma and polymyositis: Clinical associations

Rooij, D. J. De; Putte, L. B. A. Van De; Habets, W. J.; Venrooij, Walther J. van

doi:10.1007/bf02030079

Cited by 14 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From the literature search, 59 articles assessing the correlation between SSc‐associated autoantibodies and specific aspects of prognosis met the criteria for further review. Of these, 37 unduplicated series were chosen, graded “A” (8–12), and form the basis of the recommendations (Tables 4–7 (1–3, 7, 34, 36, 41, 42, 51, 53, 59, 63, 64, 70, 80–82, 85–102). It would have been desirable to include other outcomes in this analysis, such as death, disability, or renal failure.…”

Section: Indications For Clinical Use Of Aca Anti–scl‐70 and Anoa Tmentioning

confidence: 99%

“…Type II disease includes arm, leg, and face involvement, and type III disease includes truncal involvement. Twenty‐one studies were reviewed examining ACA for defining the extent of cutaneous disease (34, 41, 42, 51, 53, 59, 63, 82, 85, 87, 89–96, 98, 99, 104) (Table 4). The sensitivity of ACA in predicting the presence of lcSSC using ACR criteria (96) was 44%; specificity 93%; and positive LR of 6.1.…”

Section: Indications For Clinical Use Of Aca Anti–scl‐70 and Anoa Tmentioning

confidence: 99%

See 1 more Smart Citation

Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Reveille

Solomon

2003

Arthritis & Rheumatism

241

136

View full text Add to dashboard Cite

Section: Indications For Clinical Use Of Aca Anti–scl‐70 and Anoa Tmentioning

confidence: 99%

Section: Indications For Clinical Use Of Aca Anti–scl‐70 and Anoa Tmentioning

confidence: 99%

Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Reveille

Solomon

2003

Arthritis & Rheumatism

241

136

View full text Add to dashboard Cite

“…ACA have been found in association with a lower frequency of RLD in some studies [37,44] but not others [45,46]. It is noteworthy that ACA-positive patients are more likely to have an abnormal DL CO but a normal chest radiograph and FVC [47], underscoring that pulmonary hypertension, in the absence of hypoxia from pulmonary fibrosis, is a more common feature of ACA-positive patients with SSc.…”

Section: Acamentioning

confidence: 99%

“…Patients who are initially positive tend to remain so over time [45,68], although in one recent study some patients with milder disease became anti-Scl-70-negative later in their disease course [69]. Three studies have shown variations in anti-Scl-70 levels (determined by ELISA) with extent of disease involvement and even seronegative conversion with disease remission [68-70], although this was not seen in others [51].…”

Section: Anti-scl-70 (Anti-topoisomerase I) Antibodiesmentioning

confidence: 99%

Untitled

Reveille

2003

Arthritis Res Ther

190

View full text Add to dashboard Cite

80ACA = anti-centromere antibodies; aCL = anticardiolipin antibodies; AFA = antifibrillarin/anti-U3-RNP; ANA = anti-nuclear antibodies; ANCA = anti-neutrophil cytoplasmic antibodies; ANoA = anti-nucleolar antibodies; anti-RNAP = anti-RNA-polymerase antibodies; anti-Sm = anti-Smith antibodies; aPL = antiphospholipid antibodies; β 2 gp I = β 2 glycoprotein I antibodies; CENP = centromeric nucleoprotein; CIE = counterimmunoelectrophoresis; CREST = a variant of SSc defined by the presence of calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangectasia; CTD = connective tissue diseases; dcSSc = diffuse cutaneous systemic sclerosis; DL CO = diffusion capacity for carbon monoxide; DM = dermatomyositis; ELISA = enzyme-linked immunosorbent assay; FVC = forced vital capacity; HLA = human leukocyte antigen; IB = immunoblotting; ID = immunodiffusion; IIF = indirect immunofluorescence; IP = immunoprecipitation; lcSSc = limited cutaneous systemic sclerosis; MCTD = mixed connective tissue disease; PFT = pulmonary function tests; PM = polymyositis; PM/SSc = myositis/scleroderma overlap; RLD = restrictive lung disease; RNP = ribonucleoprotein; SLE = systemic lupus erythematosus; snRNP = small nuclear RNP; SSc = systemic sclerosis. Arthritis Research & Therapy Vol 5 No 2 Ho and Reveille IntroductionSystemic sclerosis (scleroderma or SSc) is a heterogeneous disorder characterized by autoantibody subsets, which in turn have their own clinical associations. Much controversy resides in whether these autoantibodies contribute directly to the pathology seen in SSc or whether they are merely epiphenomena of the underlying disease process. Nevertheless, various autoantibodies found in patients with SSc carry significant value in diagnosis and in predicting clinical outcomes (Fig. 1). The autoantibodies classically associated with SSc include anti-centromere antibodies (ACA) and anti-Scl-70 (otherwise known as antitopoisomerase I or anti-topo I). In addition to these is the less commonly occurring anti-nucleolar antibody (ANoA) system, which comprises a mutually exclusive heterogeneous group of autoantibodies that produce nucleolar stain- AbstractScleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic dise...

show abstract

“…Anticentromere antibodies and antitopoisomerase-I antibodies are mainly found in individuals with the scleroderma spectrum of diseases, including Raynaud's disease [1][2][3][4][5]. Each autoantibody has particular clinical associations, including gender, race, clinical subsets or clinical manifestations [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Anticentromere antibodies are associated with vascular features, and female gender [1,[3][4][5][6][7][8]16,17], and antitopoisomerase-I antibodies with extensive skin and internal organ fibrosis [3,5,9,[11][12][13][14][15]20].…”

Section: Introductionmentioning

confidence: 99%

A cross-reactive idiotype in scleroderma

Vázquez‐Abad

Tian

Zanetti

et al. 1997

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYAutoantibodies to centromere proteins (anti-CENPs) and to topoisomerase-I are highly specific for scleroderma. Unlike most autoantibodies in other diseases, these autoantibodies are mutually exclusive. We have analysed the idiotypes (Ids) expressed by anti-CENP-B, antitopoisomerase-I, and IgGs from 20 scleroderma patients. Rabbit anti-Ids were prepared to antitopoisomerase-I from two scleroderma patients, and to anti-CENP-B from four patients. These six anti-Ids were used to study the purified autoantibodies from 20 scleroderma patients: four antitopoisomerase-I, 10 anti-CENP-B, and six purified IgG from scleroderma patients who were negative for both autoantibodies. In addition, we studied sera from 40 normal autoantibody-negative controls, and sera and purified immunoglobulins from 17 systemic lupus erythematosus (SLE) patients containing high titres of anti-double-stranded DNA, and/or autoantibodies to extractable nuclear antigens (ENA). Using direct binding, and competitive inhibition ELISAs and immunoblots, we identified an Id present in the heavy chains of all the affinity-purified antitopoisomerase-I, and anti-CENP-B. Interestingly, this Id was also present in the immunoglobulins of the scleroderma patients who had neither of the two autoantibodies. By contrast, cross-reactive Id-EM was not found in the sera or immunoglobulins from 17 SLE patients, or in the sera from 40 normal subjects. Several samples from two patients showed that this cross-reactive Id-EM was stable over time. The scleroderma disease-specific autoantibodies may be identified through a common structural feature at the variable region of the heavy chain: cross-reactive Id-EM.

show abstract

Marker antibodies in scleroderma and polymyositis: Clinical associations

Cited by 14 publications

References 21 publications

Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Evidence‐based guidelines for the use of immunologic tests: Anticentromere, Scl‐70, and nucleolar antibodies

Untitled

A cross-reactive idiotype in scleroderma

Contact Info

Product

Resources

About